Targeting miRNAs for drug discovery: a new paradigm

The discovery of miRNAs and the establishment of it's clinical links with multiple diseases has led to a paradigm shift in the drug development pipeline of major pharmaceutical companies and has given birth to several biotechnology enterprises revolving around these magic molecules. The miRNA p...

Full description

Saved in:
Bibliographic Details
Published in:Current molecular medicine Vol. 10; no. 5; p. 503
Main Authors: Nagpal, J K, Rani, R, Trink, B, Saini, K S
Format: Journal Article
Language:English
Published: Netherlands 01.07.2010
Subjects:
Animals
Disease - genetics
Drug Discovery
Drug-Related Side Effects and Adverse Reactions
Humans
MicroRNAs - genetics
MicroRNAs - metabolism
Pharmacogenetics
Polymorphism, Genetic
ISSN:1875-5666, 1875-5666
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The discovery of miRNAs and the establishment of it's clinical links with multiple diseases has led to a paradigm shift in the drug development pipeline of major pharmaceutical companies and has given birth to several biotechnology enterprises revolving around these magic molecules. The miRNA profiling studies over the last few years have indicated implicit involvement of miRNAs in the pathobiology of cancer, diabetes, infectious diseases as well as cardiovascular, neurological and immune system disorders. This information is currently being translated into tools for diagnosis, prognosis and predicting response to treatment. In addition, active and vigorous investigations are ongoing in several laboratories across academia and industry to decipher the precise molecular functions and mechanism of action for key miRNAs with therapeutic potential. Knowledge gained from these efforts will surely pave the way for designing effective R&D strategies and will revolutionize the way we diagnose and treat various diseases. The present review attempts to track the evolutionary progression of microRNA research from it's early infancy years to its maturity into a dynamic field of drug discovery.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1875-5666
1875-5666
DOI:10.2174/156652410791608216